<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682938</url>
  </required_header>
  <id_info>
    <org_study_id>AI-China2020</org_study_id>
    <nct_id>NCT04682938</nct_id>
  </id_info>
  <brief_title>Prevalence, Characteristics and Prognosis of Adrenal Incidentalomas in Chinese Adults</brief_title>
  <official_title>Prevalence, Characteristics and Prognosis of Adrenal Incidentalomas in Chinese Adults: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investige the prevalence, characteristics and prognosis of adrenal incidentalomas in&#xD;
      Chinese adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the development of imaging detection technology and its wide application in clinic, the&#xD;
      detection rate of adrenal incidentaloma (AI) has been greatly improved. Most AI are benign&#xD;
      and do not have the function of autonomic hormone secretion, but about 20% of them have&#xD;
      function and can secrete adrenal hormone autonomously. Studies based on biopsy reports show&#xD;
      that the prevalence of AI is about 2%, and the prevalence of AI detected by CT scan is 1% -&#xD;
      4.5%. However, most of these studies are retrospective, and there may be selection bias and&#xD;
      other confounding factors. There is no large sample prospective study on the prevalence of AI&#xD;
      in the general population. The purpose of this study is to prospectively include patients&#xD;
      with adrenal incidentaloma in community physical examination population, and evaluate their&#xD;
      function and prognosis. The research results will provide new evidence for standardized&#xD;
      diagnosis and treatment of adrenal incidentaloma in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">March 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of PA</measure>
    <time_frame>1 years</time_frame>
    <description>To calculate the prevalence of PA in Chinese patients with adrenal incidentalomas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Cushing</measure>
    <time_frame>1 years</time_frame>
    <description>To calculate the prevalence of Cushing in Chinese patients with adrenal incidentalomas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of pheochromocytoma</measure>
    <time_frame>1 years</time_frame>
    <description>To calculate the prevalence of pheochromocytoma in Chinese patients with adrenal incidentalomas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of adrenal cortical carcinoma</measure>
    <time_frame>1 years</time_frame>
    <description>To calculate the prevalence of adrenal cortical carcinoma in Chinese patients with adrenal incidentalomas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of nonfunctional tumor</measure>
    <time_frame>1 years</time_frame>
    <description>To calculate the prevalence of nonfunctional tumor in Chinese patients with adrenal incidentalomas</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prevalence</condition>
  <condition>Adrenal Incidentaloma</condition>
  <arm_group>
    <arm_group_label>adrenal incidentalomas in Chinese community adults</arm_group_label>
    <description>Patients aged over 18 years with adrenal incidentaloma (the maximum diameter of tumor ≥ 10 mm) were found by low-dose chest CT in physical examination center.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Some subtye of disease should be diagnosed by DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese community adults&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ·patients with adrenal incidentaloma (the maximum diameter of tumor ≥ 10 mm) were found by&#xD;
        low-dose chest CT in physical examination center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with adrenal related diseases were definitely diagnosed in the past&#xD;
&#xD;
          -  Patients who are not willing to participate in and complete the study and refused to&#xD;
             sign the written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Qifu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Qifu, PhD</last_name>
    <phone>+86-023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Shuming, PhD</last_name>
    <phone>+86-023-89011552</phone>
    <email>443068494@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Chongqing Medical University, Chongqing, China</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Qifu, PhD</last_name>
      <phone>+86-023-89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
    <contact_backup>
      <last_name>Yang Shuming, PhD</last_name>
      <phone>+86-023-89011552</phone>
      <email>443068494@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ichijo T, Ueshiba H, Nawata H, Yanase T. A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J. 2020 Feb 28;67(2):141-152. doi: 10.1507/endocrj.EJ18-0486. Epub 2019 Nov 7.</citation>
    <PMID>31694993</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JM, Kim MK, Ko SH, Koh JM, Kim BY, Kim SW, Kim SK, Kim HJ, Ryu OH, Park J, Lim JS, Kim SY, Shong YK, Yoo SJ; Korean Endocrine Society, Committee for Clinical Practice Guidelines. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab (Seoul). 2017 Jun;32(2):200-218. doi: 10.3803/EnM.2017.32.2.200. Review.</citation>
    <PMID>28685511</PMID>
  </results_reference>
  <results_reference>
    <citation>Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016 Aug;175(2):G1-G34. doi: 10.1530/EJE-16-0467.</citation>
    <PMID>27390021</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Prevalence</keyword>
  <keyword>characteristics</keyword>
  <keyword>prognosis</keyword>
  <keyword>adrenal incidentaloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocortical Adenoma</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

